



**COMBINED GENERAL MEETING  
JUNE 17, 2020**

**Proposed appointments / reappointment  
to the Supervisory Board**



## VALNEVA SE - PROPOSED APPOINTMENTS / REAPPOINTMENT TO THE SUPERVISORY BOARD

*This document is a free translation. In case of discrepancy between the French and the English version, the French version shall prevail.*

1

### VALNEVA

A European company (*Societas Europaea* or SE) with a Management and a Supervisory Board

Share capital: €13,820,407.74

Registered office: 6 rue Alain Bombard, 44800 Saint-Herblain (France)

Nantes Companies Register (RCS) No. 422 497 560

---

### MS. SHARON ELIZABETH TETLOW

*PROPOSED APPOINTMENT AS SUPERVISORY BOARD MEMBER OF VALNEVA SE  
RESOLUTION No. 5 OF THE COMBINED GENERAL MEETING OF JUNE 17, 2020  
ARTICLE R. 225-83, 5° OF THE FRENCH COMMERCIAL CODE*

Ms. Sharon Elizabeth Tetlow, commonly known as Sharon Tetlow, an American national, aged 60, is a seasoned financial executive with more than three decades specializing in the life sciences industry. Ms. Tetlow founded and serves, since January 2016, as Managing Partner of Potrero Hill Advisors which provides strategic and operational financial support to life science companies through its team of Chief Financial Officers and controllers. She is a trusted partner for CEOs to help optimize their strategic outcomes, and is known for her demonstrated leadership in fundraising strategies and tactics. In this context, Ms. Tetlow works side by side with CEOs and their boards in capital and market strategy development, investor selection and targeting, terms evaluation and negotiation. From April 2013 to January 2016, Ms. Tetlow was Managing Director of Danforth Advisors, a similar financial advisory firm. Prior to this, Ms. Tetlow had a long and successful career as CFO of various public and private biotechnology companies in the United States during which she raised considerable capital and took the lead in financial and corporate strategy. Since January 2020, she serves on the Board of Directors of Catalyst Biosciences (NASDAQ: CBIO), and previously served on the Board of Armetheon, a private biotechnology company (from November 2016 to September 2017). Ms. Tetlow is currently on the Board of Katherine Michiels School Project Open Mind, an education-related not-for-profit in San Francisco. Ms. Tetlow earned a B.A. from the University of Delaware and M.B.A. from Stanford University.

Currently, Ms. Tetlow does not hold any Valneva shares.



**MS. JOHANNA WILLEMINA PATTENIER**

*PROPOSED APPOINTMENT AS SUPERVISORY BOARD MEMBER OF VALNEVA SE  
RESOLUTION No. 6 OF THE COMBINED GENERAL MEETING OF JUNE 17, 2020  
ARTICLE R. 225-83, 5° OF THE FRENCH COMMERCIAL CODE*

Ms. Johanna Willemina Pattenier, a Dutch national, aged 60, is a seasoned executive with more than two decades of market access, medical and commercial experience in the pharmaceutical industry. From 2015-2017, Ms. Pattenier was the Site Head of Novartis Vaccines and Diagnostics in Basel (Switzerland), a GSK (GlaxoSmithKline) company, and led as CEO a global organization consisting of all functions with the focus on business continuity, while preparing for closure of the Basel site. Prior to this, Ms. Pattenier had a long and successful international career at Novartis (2009-2015) and GSK (1999-2009) where she held various global market access, commercial and medical roles in different countries, culminating in her role as Executive management team member and Head of global public health and market access at Novartis, also in Basel. Prior to joining GSK, Ms. Pattenier worked in commercial and medical roles at other pharmaceutical companies in Germany, Organon (1993-1999) and Byk Gulden (1990-1992). Ms. Pattenier received various internal awards for outstanding contributions to the business and portfolio transformation teams. Ms. Pattenier holds a medical degree from the University of Homburg/Saar, Germany and studied Medicine in Rotterdam, the Netherlands.

Currently, Ms. Pattenier does not hold any Valneva shares.



**VALNEVA SE - PROPOSED APPOINTMENTS / REAPPOINTMENT TO THE SUPERVISORY BOARD**

*This document is a free translation. In case of discrepancy between the French and the English version, the French version shall prevail.*

3

**MR. THOMAS CASDAGLI**

*PROPOSED RATIFICATION OF APPOINTMENT AND REAPPOINTMENT  
AS SUPERVISORY BOARD MEMBER OF VALNEVA SE  
RESOLUTIONS No. 7 AND 8 OF THE COMBINED GENERAL MEETING OF JUNE 17, 2020  
ARTICLE R. 225-83, 5° OF THE FRENCH COMMERCIAL CODE*

Mr. Thomas Casdagli, a British national, aged 43, joined MVM Partners in 2002 and has 17 years experience in investing in innovative life science companies. Before joining MVM, he qualified as a chartered accountant at PricewaterhouseCoopers' Private Equity and Venture Capital practice. Mr. Casdagli has an MBioch in Molecular and Cellular Biochemistry from Oxford University and is currently a member of the Boards of eZono AG (since August 2019), Xention Pharma Ltd. (since January 2016), Onbone Oy (since November 2014) and Patient Connect Ltd. (since November 2011).

Currently, Mr. Casdagli does not hold any Valneva shares directly, but has an economic interest in 63,993 shares held in entities managed by MVM Partners LLP.